12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

The Problem: Typing Antigens on IgG-Coated (DAT-Positive) Red Cells

When a patient's red cells are heavily coated with IgG - from a warm autoantibody, hemolytic disease of the fetus and newborn, or a hemolytic transfusion reaction - routine antigen typing becomes unreliable. Many antisera protocols include an antihuman globulin (IAT) phase, and endogenous IgG already sitting on the membrane will react with the anti-IgG reagent regardless of whether the antiserum's target antigen is actually present, producing a false-positive result. The transfusion service still needs an accurate extended phenotype on these patients - most urgently to select antigen-matched (phenotype-matched) donor units for a patient with a warm autoantibody, or to confirm a newborn's Rh type during an HDFN workup. The solution is to chemically strip the bound IgG from the membrane before typing, using a method gentle enough to leave the antigens themselves intact.

Why not just use the elution methods from Section 12.2?

This is a common point of confusion. The acid, heat, and freeze-thaw elution methods covered in Section 12.2 are optimized to harvest antibody for identification - they deliberately favor efficient antibody release over preserving the cell, and the treated cell itself is typically discarded once the eluate is collected. Chloroquine diphosphate and EGA solve the opposite problem: they are optimized to preserve the red cell well enough that it can still be phenotyped afterward, at the cost of being less aggressive antibody-removal methods. Choosing the wrong tool - trying to phenotype a cell after acid elution, or trying to identify antibody specificity from a chloroquine wash - is a classic exam distractor.

Chloroquine Diphosphate (CDP)

Chloroquine diphosphate dissociates IgG from the red cell membrane without significantly damaging the membrane structure for most blood group systems - a real advantage over harsher stripping methods like acid or heat elution, which can damage the membrane along with removing the antibody.

Procedure and limitations

• Incubate the DAT-positive red cells with chloroquine diphosphate at room temperature, typically checked at intervals up to roughly 2 hours (occasionally extended further if the DAT is still positive).
• Wash the cells and retest the DAT to confirm it is now negative before proceeding to phenotype with antisera; if the DAT is still positive, the residual IgG can still cause false-positive antigen typing.
• Complement is not removed by chloroquine - if the DAT positivity is due to bound complement (C3d) rather than IgG, chloroquine will not resolve it.
• Kell system antigens are denatured by chloroquine treatment, so chloroquine-treated cells cannot be used to type for K, k, or other Kell antigens - Rh, Duffy, Kidd, and MNS remain testable.
• Some cells hemolyze during the incubation; if this happens, the result is uninterpretable and testing must be repeated on a fresh sample.
• Chloroquine diphosphate solution is typically prepared or purchased as a working reagent with a defined shelf life once opened; laboratories should follow the manufacturer's storage and stability instructions rather than assume indefinite use, since a degraded reagent may fail to fully dissociate IgG and give a falsely persistent positive DAT.

EDTA-Glycine Acid (EGA)

EGA is a combination reagent that removes both IgG and complement (C3b/C3d) from the red cell membrane, addressing chloroquine's complement blind spot.

Procedure and limitations

• EGA works much faster than chloroquine - commonly complete within about 5 minutes at room temperature, versus chloroquine's roughly 2-hour incubation. This makes EGA the better choice when a phenotype result is needed quickly, such as before an urgent transfusion decision.
• Like chloroquine, EGA also denatures Kell system antigens, so EGA-treated cells cannot be used for Kell phenotyping either.
• Rh, Duffy, Kidd, MNS, and Lewis antigens are preserved and testable after EGA treatment.

Comparing chloroquine diphosphate and EGA

Applying the Method: Worked Scenario

A patient with warm autoimmune hemolytic anemia has a 3+ positive DAT (IgG-coated) and needs an extended Rh phenotype so the transfusion service can select Rh-phenotype-matched donor units before an urgent transfusion. Standard antisera testing on the untreated cells is uninterpretable because the endogenous IgG reacts with any reagent requiring an IAT phase.

Because the transfusion is urgent, the technologist chooses EGA for its roughly 5-minute turnaround rather than chloroquine's 2-hour incubation. After EGA treatment, the DAT is confirmed negative, and Rh phenotyping (D, C, c, E, e) proceeds normally since Rh antigens survive EGA treatment. If the physician had also needed a Kell phenotype for this patient, neither chloroquine nor EGA would work - both denature Kell antigens - so the laboratory would instead turn to molecular (genotyping) methods, which read the underlying DNA sequence rather than depend on an intact antigen-antibody reaction, to determine Kell status.

The same logic extends beyond this one scenario: whenever a patient's own red cells are unreliable for serologic antigen typing - heavy IgG coating, recent transfusion creating a mixed cell population (Section 12.3), or a chemically-labile antigen like Kell - genotyping is the fallback that sidesteps the underlying serologic problem entirely rather than trying to force a serologic workaround. Recognizing which problem calls for a chemical dissociation method (chloroquine/EGA) versus a genotyping referral versus a cell-separation technique is exactly the kind of applied decision the SBB exam tests, more so than memorizing incubation times in isolation.